Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age
Go back to Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age| Pfizer Inc. (NYSE: PFE) | Delayed: 24.72 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.72 | 52 Week High | $37.39 | |||
| Open | $24.72 | 52 Week Low | $28.25 | |||
| Day High | $24.72 | P/E | 14.98 | |||
| Day Low | $24.72 | EPS | $1.65 | |||
| Volume | 122,343 | |||||
